POU2F2 identified as a key oncogenic and immunomodulatory factor in kidney cancer
POU2F2 is upregulated in kidney renal clear cell carcinoma and correlates with poor prognosis and macrophage polarization.
Company
Pharmaceutical intelligence for oncology therapeutics with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.